Verition Fund Management
CHRS icon

Verition Fund Management’s Coherus Oncology CHRS Stock Holding History

Verition Fund Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-45,854
Closed -$153K – 2794
2023
Q4 		$153K Sell
45,854
-15,535
-25% -$41.6K ﹤0.01% 2100
2023
Q3 		$230K Buy
61,389
+10,500
+21% +$48.5K ﹤0.01% 1899
2023
Q2 		$217K Buy
50,889
+1,800
+4% +$10.6K ﹤0.01% 1788
2023
Q1 		$336K Buy
+49,089
New +$381K ﹤0.01% 1451
2022
Q4 		– Sell
-10,671
Closed -$103K – 2219
2022
Q3 		$103K Buy
+10,671
New +$108K ﹤0.01% 2620

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Verition Fund Management's CHRS Position: Q1 2024 in Review

Verition Fund Management sold out of Coherus Oncology (CHRS) in Q1 2024, closing a stake of 45,854 shares — an estimated $153K sold.

Verition Fund Management first reported a position in CHRS in Q3 2022 and held it in 5 quarters. The position peaked at $336K in Q1 2023. 137 funds tracked by Wall St. Rank hold CHRS as of Q1 2024.

  • Verition Fund Management reported no remaining Coherus Oncology position as of Q1 2024 after selling out during the quarter.
  • Verition Fund Management sold 45,854 Coherus Oncology shares in Q1 2024, an estimated $153K.
  • Verition Fund Management first reported a position in Coherus Oncology in Q3 2022 and held it in 5 quarters.
  • Verition Fund Management's Coherus Oncology position peaked at $336K in Q1 2023.
  • 137 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2024.

Based on Verition Fund Management's 13F filing for Q1 2024, filed 14 May 2024.